Yves Vanrenterghem
Overview
Explore the profile of Yves Vanrenterghem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
3685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Claes K, Bammens B, Kuypers D, Meijers B, Naesens M, Sprangers B, et al.
Nephrol Dial Transplant
. 2014 Jun;
29(10):1965-72.
PMID: 24957811
Background: Although renal transplantation (Tx) improves the outcome of patients with renal disease, cardiovascular (CV) risk remains high. Recently, it was demonstrated that asymmetric dimethylarginine (ADMA) levels predict CV events...
2.
Bammens B, Peeters D, Jaekers J, Claes K, Evenepoel P, Kuypers D, et al.
Kidney Int
. 2014 Jun;
86(5):1001-6.
PMID: 24940799
Functional catheter problems are a major challenge for peritoneal dialysis (PD) programs. Here we performed a retrospective single-center study of 110 consecutive patients receiving a first PD catheter (swan neck...
3.
Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F, et al.
N Engl J Med
. 2013 Nov;
369(19):1797-806.
PMID: 24195547
Background: The intrarenal resistive index is routinely measured in many renal-transplantation centers for assessment of renal-allograft status, although the value of the resistive index remains unclear. Methods: In a single-center,...
4.
Viaene L, Meijers B, Bammens B, Vanrenterghem Y, Evenepoel P
Perit Dial Int
. 2013 Nov;
34(1):71-8.
PMID: 24179107
Unlabelled: Background: High serum concentrations of the protein-bound uremic retention solutes p-cresyl sulfate (PCS) and indoxyl sulfate (IndS) and inflammation are associated with increased cardiovascular morbidity and mortality in chronic...
5.
de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers D
Pharmacogenomics
. 2013 Sep;
14(12):1467-80.
PMID: 24024898
Background & Aim: In vitro studies have identified both midazolam and tacrolimus as dual CYP3A4 and CYP3A5 substrates. In vivo; however, the CYP3A5 genotype has a marked impact on tacrolimus...
6.
De Vusser K, Lerut E, Kuypers D, Vanrenterghem Y, Jochmans I, Monbaliu D, et al.
J Am Soc Nephrol
. 2013 Aug;
24(11):1913-23.
PMID: 23949799
The effect of baseline histology and individual histologic lesions at the time of transplantation on long-term graft survival has been evaluated using different scoring systems, but the predictive capacity of...
7.
Claes K, Heye S, Bammens B, Kuypers D, Meijers B, Naesens M, et al.
Transpl Int
. 2013 Jul;
26(10):973-81.
PMID: 23870026
Renal transplant recipients have an increased risk of cardiovascular (CV) disease. Arterial stiffness (AS) and aortic calcifications (ACs) are well-known CV risk factors in patients with chronic kidney disease. We...
8.
Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, et al.
Clin J Am Soc Nephrol
. 2013 Jul;
8(9):1508-14.
PMID: 23813557
Background And Objectives: p-Cresyl sulfate and indoxyl sulfate contribute to cardiovascular disease and progression of renal disease. Renal clearance of both solutes mainly depends on tubular secretion, and serum concentrations...
9.
Vanhove T, Kuypers D, Claes K, Evenepoel P, Meijers B, Naesens M, et al.
Transpl Int
. 2013 Jun;
26(8):813-21.
PMID: 23746202
Unlabelled: Mycophenolate mofetil (MMF) decreases the risk of acute rejection and is associated with improved graft survival in renal transplant recipients. However, MMF-related side effects often necessitate dose reduction, which...
10.
Kuypers D, Peeters P, Sennesael J, Kianda M, Vrijens B, Kristanto P, et al.
Transplantation
. 2012 Dec;
95(2):333-40.
PMID: 23263559
Background: With effective agents available to prevent posttransplantation acute organ rejection, medication adherence becomes a key factor for successful treatment outcomes after renal transplantation. A once-daily, modified-release oral formulation of...